

## PsA Patients With Depressive Symptoms Have A Lower Chance of Achieving Remission - Data From The RABBIT-SpA Register

Andreas Reich<sup>1</sup>, Anja Weiß<sup>1</sup>, Lisa Lindner<sup>1</sup>, Martin Feuchtenberger<sup>2</sup>, Georg Dahmen<sup>3</sup>, Hanns-Martin Lorenz<sup>4</sup>, Xenofon Baraliakos<sup>5, 6</sup>, Anne C. Reigerer<sup>1</sup>

<sup>1</sup>German Rheumatology Research Center, Epidemiology and Health Services Research, Berlin, Germany, <sup>2</sup>InnKlinikum, Department of Internal Medicine II, Burghausen, Germany,

<sup>3</sup>Rheumatologist, Hamburg, Germany, <sup>4</sup>Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg, Germany, <sup>5</sup>Ruhr University Bochum, Bochum, Germany, <sup>6</sup>Rheumazentrum Ruhrgebiet, Herne, Germany,

### AIM

Effect of depressive symptoms at initiation of a new systemic therapy on remission after 3 and 6 months.

### METHOD

- Baseline depressive symptoms: WHO-5  $\leq 29/100$  = moderate/severe;  $> 29$  none/mild
- Minimal Disease Activity / DAPSA remission
- Multiple imputation of missing data
- Logistic regression (Exposure WHO-5, outcome remission at 3 and 6 months)

### RESULTS

Patients with moderate/severe depressive symptoms:

- have worse disease activity scores and patient reported outcomes
- achieve remission less often than patients with no or mild symptoms


After adjusting for relevant confounding variables, patients with a higher WHO-5 score have a higher chance of achieving remission.

### CONCLUSIONS

- Depressive symptoms independently impacted the likelihood of achieving remission.
- Clinicians should prioritize screening for depression.

# Key finding: Depressive Symptoms Negatively Affect Chance of Remission in PsA Patients

### Odds Ratios for Effect of WHO-5 Well-being Index on Achieving Remission Criteria (per 10 Points)




Project Homepage

Funding: RABBIT-SpA is currently supported by a joint, unconditional grant from AbbVie, Amgen, Biocon Biologics, Biogen, Celltrion, Hexal, Johnson & Johnson, Lilly, Novartis, Pfizer and UCB.


andreas.reich@drfz.de

### MDA by Depressive Symptoms and Time

#### No/mild depressive symptoms



#### Moderate/severe depressive symptoms




#### Baseline Characteristics by Depressive Symptoms

	Moderate/severe N=516 (29%)	None/mild N=1272 (71%)
Female, n (%)	348 (67)	717 (56)
Age (years), mean $\pm$ SD	52 $\pm$ 11.2	52.5 $\pm$ 12.8
$\geq 3$ Comorbidities, n (%)	198 (38)	359 (28)
Obesity (BMI $\geq 30$ ), n (%)	226 (44)	447 (35)
Current smoker, n (%)	177 (34)	359 (28)
DAPSA, mean $\pm$ SD	33.1 $\pm$ 18.4	26.5 $\pm$ 18.2
BSA, mean $\pm$ SD	8.3 $\pm$ 15.1	7.7 $\pm$ 13.7
HAQ, mean $\pm$ SD	1.3 $\pm$ 0.6	0.8 $\pm$ 0.6
Patient global, mean $\pm$ SD	6.9 $\pm$ 2.1	5.2 $\pm$ 2.3

#### MDA criteria by Depressive Symptoms and Time

##### 0 months 3 months 6 months



Baseline depressive symptoms      Moderate/severe      None/mild